<scp>PD</scp>‐1 expression on peripheral blood T‐cell subsets correlates with prognosis in non‐small cell lung cancer
Kayoko Waki(Frederick National Laboratory for Cancer Research), Akira Yamada(Fujita Health University), Koichi Yoshiyama(Kurume University), Nobukazu Komatsu(Kurume University), Shinzo Takamori(Kurume University), Yasuhiro Terazaki(Kurume University), Satoko Matsueda(Kurume University), Shunichi Sugawara(Sendai Kousei Hospital), Teppei Yamada(Harvard University), Kyogo Itoh(Kurume University), Shinjiro Sakamoto(Kurume University)
Cited by 93
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695